Non-animal technologies (NATs) are emerging as human-relevant in vitro platforms that enable researchers to explore the biological mechanisms underpinning health and disease. These systems – including organs-on-chips, organoids, and advanced 2D and 3D microphysiological systems – allow the study of human biology in both healthy and diseased states, and supporting the development of more effective and human-relevant drug and cell therapies.

At CeMi, our vision is to integrate bioengineering and biomaterials approaches with human biology to develop and translate innovative NATs. These platforms are designed to be robust tools for fundamental discovery science, while also accelerating the delivery of safe and effective therapies to patients.

We focus on creating well-defined, biomaterial-based extracellular microenvironments that enable precise control over cell behaviour, while maintaining minimal system complexity.

We are also committed to training the next generation of researchers in NATs, including through the LifETIME Centre for Doctoral Training. We work closely with clinicians, charities, and industry partners to develop impactful and clinically relevant next-generation NAT models.